News Lundbeck preps for key bexicaserin data around year-end Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.
News EpiWatch app detects major seizures with few false alarms An Apple Watch patient monitoring app can help people with epilepsy reduce the risk of sudden death, with high sensitivity and a low false alarm rate.
R&D Why UCB bet a billion dollars on cell therapy for epilepsy UCB's chief science officer spoke to pharmaphorum about why Neurona's in-development cell therapy could be a game changer for epilepsy treatment.
News Angelini seeks US beachhead with $4.1bn Catalyst buy Angelini has agreed to buy Catalyst Pharma for up to $4.1bn, its first acquisition since 2021, which would mark its entry into the US market.
News UCB cuts $1.15bn deal to buy epilepsy biotech Neurona UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.
News Praxis soars on rare childhood epilepsy trial data Praxis looks like it could be filing for approval of two products next year, after its childhood epilepsy drug delivered a win in a pivotal trial.
News TransThera's resistant biliary cancer drug cleared in China TransThera's Yochanra has been cleared in China as the world's first drug that can overcome resistance to FGFR inhibitors in cholangiocarcinoma.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
